Wegovy vs. Trulicity
See how Wegovy and Trulicity compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Wegovy and Trulicity are both once-weekly GLP-1 receptor agonist injections, but Wegovy is approved for weight management while Trulicity is approved for type 2 diabetes.
Wegovy reduces cardiovascular risk in adults with obesity or overweight and heart disease, while Trulicity does so specifically in adults with type 2 diabetes.
Both drugs carry a boxed warning for thyroid tumors and cause similar gastrointestinal side effects like nausea and diarrhea.
Wegovy vs. Trulicity Drug Summary
Wegovy
Wegovy is a GLP-1 receptor agonist (semaglutide) approved for chronic weight management in adults and adolescents with obesity or overweight, and to reduce cardiovascular risk in adults with established heart disease. It's injected once a week, starting at a low dose and increasing every four weeks up to a 2.4 mg maintenance dose.
Trulicity
Trulicity is a GLP-1 receptor agonist (dulaglutide) approved to control blood sugar in adults and children 10 and older with type 2 diabetes, and to lower cardiovascular risk in adults with type 2 diabetes and heart disease or risk factors. It's given as a once-weekly injection with a prefilled pen, starting at 0.75 mg and increasing as needed up to 4.5 mg.
Wegovy vs. Trulicity Side Effects
Wegovy
Trulicity
Wegovy vs. Trulicity Dosage
Wegovy
Trulicity
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 0.75 mg once weekly | Weeks 1-4 |
| Maximum dose | 4.5 mg once weekly | If needed |
| Dose changes | 3 increases | Every 4 weeks |
Wegovy
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2.4 mg once weekly | Week 17 onward |
| Dose changes | 4 increases | Every 4 weeks |
Trulicity
| STAGE | DOSE | WHEN |
| Starting dose | 0.75 mg once weekly | Weeks 1-4 |
| Maximum dose | 4.5 mg once weekly | If needed |
| Dose changes | 3 increases | Every 4 weeks |
Wegovy vs. Trulicity Indications
Wegovy
Wegovy is FDA-approved for chronic weight management alongside diet and exercise in adults and teens 12 and older with obesity or overweight plus a weight-related condition. It's also approved to reduce the risk of major cardiovascular events in adults with obesity or overweight and existing heart disease.
Chronic weight management in adults with obesity or overweight
Approved for adolescents 12 and older
Reduces risk of heart attack, stroke, and cardiovascular death
Requires a weight-related condition or established heart disease
Not approved for diabetes blood sugar control
Trulicity
Trulicity is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes, alongside diet and exercise. It's also approved to lower the risk of major cardiovascular events in adults with type 2 diabetes who have heart disease or multiple risk factors.
Blood sugar control in adults with type 2 diabetes
Approved for children 10 and older with type 2 diabetes
Reduces cardiovascular risk in adults with type 2 diabetes
Sometimes used off-label for weight loss without diabetes
Not approved as a primary weight-loss treatment
Wegovy vs. Trulicity Pros and Cons
Wegovy
Wegovy uses a higher maintenance dose than diabetes-focused semaglutide products, which may translate to greater weight loss. It carries the same boxed warning for thyroid tumors as other GLP-1 drugs and shares similar gastrointestinal side effects with Trulicity.
Pros
FDA-approved specifically for weight management, not just off-label use
Approved to reduce cardiovascular risk in people without diabetes
Approved for adolescents 12 and older
Uses a higher maintenance dose (2.4 mg) than diabetes GLP-1 options
Cons
Not approved for blood sugar control in type 2 diabetes
Newer drug (2021) with less long-term real-world data
Higher rates of nausea and diarrhea reported in trials
No pediatric type 2 diabetes indication
Trulicity
Trulicity has been on the market since 2014, giving it a longer track record than Wegovy. It's specifically approved for type 2 diabetes and pediatric use, but any weight-loss benefit is considered off-label.
Pros
Longer track record with over a decade of real-world use
Approved for children as young as 10 with type 2 diabetes
Lower reported rates of nausea and diarrhea in trials
Available in multiple maintenance doses for gradual adjustment
Cons
No FDA-approved weight-loss indication; use for weight loss is off-label
Not approved to treat obesity or overweight without diabetes
Lower maximum dose may mean less weight loss than Wegovy
Cardiovascular benefit only established in people with type 2 diabetes
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.